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Perilipin 5 and liver fatty acid binding protein function to
restore quiescence in mouse hepatic stellate cells
Jianguo Lin,*,† Shizhong Zheng,§ Alan D. Attie,** Mark P. Keller,** David A. Bernlohr,††
William S. Blaner,§§ Elizabeth P. Newberry,*** Nicholas O. Davidson,1,*** and Anping Chen1,*

Abstract Hepatic stellate cell (HSC) activation occurs along
with decreased Perilipin5 (Plin5) and liver fatty acid-binding
protein (L-Fabp) expression and coincident lipid droplet
(LD) depletion. Conversely, the activated phenotype is reversible in WT HSCs upon forced expression of Plin5. Here,
we asked if L-Fabp expression is required for Plin5-mediated
rescue of the quiescent phenotype. Lentiviral Plin5 transduction of passaged L-Fabp/ HSCs failed to reverse activation markers or restore lipogenic gene expression and LD
formation. However, adenoviral L-Fabp infection of lentiviral Plin5 transduced L-Fabp/ HSCs restored both the quiescent phenotype and LD formation, an effect also mediated
by adenoviral intestine-Fabp or adipocyte-Fabp. Expression
of exogenous Plin5 in activated WT HSCs induced a transcriptional program of lipogenic gene expression including
endogenous L-Fabp, but none of the other FABPs. We further demonstrated that selective, small molecule inhibition
of endogenous L-Fabp also eliminated the ability of exogenous Plin5 to rescue LD formation and reverse activation of
WT HSCs. This functional coordination of L-Fabp with Plin5
was 5′-AMP-activated protein kinase (AMPK)-dependent and
was eliminated by AMPK inhibition. Taken together, our
results indicate that L-Fabp is required for Plin5 to activate a
transcriptional program that restores LD formation and reverses HSC activation.—Lin, J., S. Zheng, A. D. Attie, M. P.
Keller, D. A. Bernlohr, W. S. Blaner, E. P. Newberry, N. O. Davidson, and A. Chen. Perilipin 5 and liver fatty acid binding
protein function to restore quiescence in mouse hepatic stellate cells. J. Lipid Res. 2018. 59: 416–428.
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Nonalcoholic fatty liver disease encompasses a spectrum
of pathology ranging from simple steatosis to nonalcoholic
steatohepatitis (NASH) and cirrhosis, but the mechanisms
and mediators that regulate necroinflammation and disease progression are still poorly understood (1–3). NASHassociated hepatic fibrosis is currently the target of
significant scientific and clinical interest, in particular, the
mechanisms regulating activation of hepatic stellate cells
(HSCs), which are the major fibrogenic effectors (1–3).
Quiescent HSCs contain abundant complex lipids that are
localized within lipid droplets (LDs) (1–3). Upon HSC activation and the induction of fibrogenesis, HSCs undergo
loss of LDs along with enhanced proliferation, de novo expression of -smooth muscle actin (-SMA), and overproduction of extracellular matrix, including I(I) collagen.
Among the most abundant proteins on LDs are members of the perilipin (Plin) family of lipid droplet proteins,
some of which (e.g., Plin2) play important roles in the regulation of lipid metabolism in a variety of tissues including
liver (4–7). Our previous observations demonstrated that
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MATERIALS AND METHODS
Animal studies
The animal protocols for the use of mice in this study were approved by the Institutional Animal Care and Use Committees of
Saint Louis University and Washington University in St. Louis and
followed guidelines issued by the National Institutes of Health.
Congenic L-Fabp knockout mice (L-Fabp/) were generated and
maintained as described previously (18). WT male and female
C57BL/6J mice were purchased from Jackson Laboratory, Bar
Harbor, MA, and were housed in a temperature-controlled animal facility (23°C) with a 12:12 h light-dark cycle and allowed free
access to regular chow and water. Male and female WT and
L-Fabp/ mice were maintained on a standard rodent chow diet
(PicoLab Rodent Diet 20) and mice of comparable ages (12–16
weeks) were used for isolation of HSCs for experiments.

Isolation and culture of HSCs
HSCs were isolated by pronase-collagenase perfusion in situ before density gradient centrifugation, as previously described (19).
Freshly isolated HSCs were cultured in DMEM supplemented
with 20% FBS. Cells were passaged in DMEM with 10% FBS. Unless otherwise indicated, semi-confluent HSCs with four to nine

passages were used in all experiments. In some experiments, lentivirus transduced HSCs were treated with L-Fabp inhibitors (supplemental Fig. S1), at the indicated doses for 24 h. All FABP
inhibitors were synthesized by a commercial vendor on a contract
basis (Nanosyn, Santa Clara, CA). Compound purity was determined by LC-MS, and was >98% for all compounds. The design of
these inhibitors was based on structural similarity to 8-anilinonaphthalene-1-sulfonic acid (1, 8 ANS), which contains both a sulfonic acid and an amine group and competes for binding within
the ligand binding pocket of hydrophobic ligand binding proteins as determined using a displacement assay as previously described (20). Purified recombinant FABP from liver, intestine,
epithelium, heart, and adipose were used to evaluate compound
selectivity experimentally. 1,8-ANS fluorescence (480 nm emission; 397 nm excitation) was determined in response to 6 µM purified FABP protein, 500 nM 1,8-ANS, and varying amounts of one
of the test compounds in a final volume of 50 µl. A ten-point compound concentration series ranging from 0.7 – 100 µM was used
to determine an IC50 for each compound to displace 1,8-ANS
from the ligand-binding pocket of each FABP isoform. Oleic acid
was used as a positive control, and yielded an apparent IC50 of
7 µM. Compounds NSOP313 and NSOP373 were the most selective for liver FABP, with IC50 values of 3.7 µM and 7.2 µM, respectively; for all other FABP isoforms, these compounds demonstrated
IC50 values >100 µM. Compounds NSOP318 and NSOP364 were
the most potent for liver FABP, with IC50 values of 1.5 µM and 1.8
µM, but substantial binding to the adipose and epithelial FABP
isoforms was observed. NSOP325 was the least potent compound
for liver FABP (IC50 9 µM), and showed significant binding to
all five FABP isoforms. Owing to the combination of high potency
and selectivity toward liver FABP, NSOP313 was used for the studies reported. Where indicated, the AMPK inhibitor Compound C
(Sigma, St Louis, MO) was added as indicated in the Fig. 6 legend
at a dose of 20 µM (8).

RNA extraction and real-time PCR
Total RNA was extracted from cells by TRI-Reagent, following
the protocol recommended by the manufacturer (Sigma). Total
RNA was treated with DNase I before the synthesis of the first
strand of cDNA. Real-time PCR was performed as previously described using SYBR Green Supermix (21). mRNA levels were expressed as fold change after normalization with GAPDH, as
described by Schmittgen et al. (22). Threshold cycle (Ct) value
used in this report for the housekeeping gene GAPDH was 18–20.
Ct values for other target genes and corresponding controls were
within a range of 25–30. Representative Ct values for Plin5 in quiescent and activated HSCs are reported in the figure legend for
Fig. 1. Fold change values are presented as 2-Ct. Ct values higher
than 35 were considered not detectable. The primers used in realtime PCR were previously described (8).

Recombinant expression constructs, antisera, and
immunoblots
Construction of the recombinant lentiviral (LV)-Plin5-yellow
fluorescent protein (YFP) and the control LV-YFP were as previously described (8). Recombinant adenoviral (Ad)-L-Fabp with
expression of FLAG epitope-tagged L-Fabp, or recombinant adenoviral Ad-LacZ with expression of LacZ were previously described and used (18). Ad-I-Fabp was constructed using a mouse
I-Fabp cDNA containing three copies of the FLAG epitope tag at
the N terminus and cloned into the pVQ AdCMV shuttle plasmid
for recombination, amplification, and purification (ViraQuest
Labs). Ad-A-Fabp was generated as previously described (23). In
brief, the expression construct was recombined into pADEasy in
Escherichia coli BJ5183 cells and transfected (Lipofectamine, Invitrogen) into 293 cells (American Type Culture Collection, Manassas,
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activation of WT mouse HSCs was coupled to a dramatic
reduction in expression of Plin5, both in vitro and in vivo
(8). In addition, other work in Plin5 knockout mice indicated that Plin5 prevented hepatic lipotoxicity, suggesting
a broader role for this LD protein in the regulation of hepatic fibrogenesis (9). In keeping with this suggestion, we
recently reported that exogenous Plin5 significantly increased intracellular lipid content and restored LDs in
HSCs from WT mice (8). In addition, the expression of
exogenous Plin5 attenuated intracellular oxidative stress in
WT HSCs (8). These actions collectively resulted in attenuated HSC activation (8) and support the concept that preserving lipid content by modulating turnover of HSC LDs
may promote a quiescent state (10, 11) and could be a
functional strategy for inhibiting fibrogenesis (10, 11).
Other players involved in HSC lipid metabolism include
members of the fatty acid-binding protein (FABP) family of
lipid-binding proteins, which are involved in the uptake,
transport, and metabolism of FAs, retinoids, and other
lipid ligands (12). Among these FABPs, liver Fabp (L-Fabp,
Fabp1) is abundantly expressed in both hepatocytes and
enterocytes and plays a key role in high-fat diet-induced
hepatic steatosis (13–17) and also in the development and
progression of diet-induced NASH in vivo (18). L-Fabp is
also abundantly expressed in quiescent HSCs, and our previous work demonstrated that activation of WT HSCs is
coupled to decreased L-Fabp expression, temporally related
to LD depletion, and reversed upon adenoviral-mediated
L-Fabp rescue (18).
Here, we sought to expand understanding of the pathways that regulate HSC activation and LD turnover in relation to mechanisms of lipid-mediated liver injury. Our
specific questions centered on the role of L-Fabp expression as a requisite component of Plin5-mediated rescue of
HSC quiescence, including LD formation and reversal of
the activated phenotype.
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VA) to allow packaging and amplification. Large scale adenovirus
preparations were obtained from 10 cm plates in which the media
was collected, centrifuged at 20,000 g for 10 min to pellet the cellular debris, and the supernatant containing virus particles recovered and frozen in aliquots at 70°C. Antisera to FABPs and
perilipins were previously described (16). Western blotting
analyses were conducted as we previously described (8). Thirty
micrograms of proteins per well were used in all immunoblots,
except where indicated as in Fig. 1.

Knockdown of perilipin 2 by shRNA

Plasmids, transient transfection, and luciferase activity
assays
The luciferase reporter plasmid pPPRE-Luc contains three
copies of peroxisome proliferator response elements (PPREs)
from the acyl-CoA oxidase gene, as we previously described (25).
The luciferase reporter plasmid LXR-Luc has three copies of liver
X receptor (LXR) binding elements. It was a gift from Dr. Knut
Steffensen (26). The plasmid TOPFlash is a Wnt/-catenin signaling luciferase activity reporter. It was kindly provided by Dr. Randall
Moon (27). Plasmid transfection and luciferase activity assays were
undertaken as previously described (28).

In situ quantification of LDs and lipid assays
Oil Red O staining was undertaken on HSCs seeded on autoclaved cover slips in a 6-well plate and cultured in DMEM with
10% FBS with or without transduction and/or treatment, followed by fixation with 4% paraformaldehyde (30 min). LDs were
stained as previously described (28). Numbers of LDs in Oil Red
O-stained HSCs were quantified using the Nuance multispectral
imaging system (Perkin-Elmer, MA), as we previously described
(18). Cells of interest were digitized and circled individually
within the image and the numbers of LDs per cell automatically
calculated. Positive staining was adjusted by subtracting background control signals. The results were collected and expressed
as a mean number of LDs per cell based on at least 10 cells. Intracellular FFAs and triglycerides (TG) were colorimetrically determined using kits from BioVision, Inc. (Mountain View, CA),
following the manufacturer’s protocol (29).

Analysis of cellular retinol and retinyl esters
WT-passaged HSCs were transduced with or without LV-Plin5YFP, or LV-YFP, or LV-Plin5-YFP plus Ad-L-Fabp. HSC concentrations of retinol and retinyl esters were determined by HPLC
protocols described previously (30). Briefly, frozen HSC pellets
were resuspended and homogenized in 1.0 ml of ice-cold PBS (10
mM sodium phosphate, pH 7.2, 150 mM sodium chloride) using
a Polytron homogenizer (Brinkmann Instruments, Westbury, NY)
set at half-maximal speed for 10 s. The HSC homogenate was then
treated with an equal volume of absolute ethanol containing a
known amount of retinyl acetate as an internal standard. The retinoids present in the homogenates were extracted into hexane.
After one backwash against doubly distilled water, the hexane extract was evaporated to dryness under a gentle stream of nitrogen.
Immediately upon reaching dryness, the retinoid-containing film
was redissolved in 40 µL of benzene for injection onto the HPLC
column. The extracted retinoids were separated on a 4.6 × 250
mm Ultrasphere C18 column (Beckmann, Fullerton, CA) preceded by a C18 guard column (Supelco, Bellefonte, PA) using
70% acetonitrile-15% methanol-15% methylene chloride as the
running solvent flowing at 1.8 ml/min. Retinol and individual
retinyl esters (retinyl palmitate, oleate, linoleate, and stearate)
were detected at 325 nm and identified by comparing the retention times and spectral data of experimental compounds with
those of authentic standards. Concentrations of retinol and retinyl esters in the HSCs were quantitated by comparing integrated
peak areas of each retinoid against those of known amounts of
purified standards. Loss during extraction was accounted for by
adjusting for the recovery of internal standard added immediately
after homogenization of the samples.

Statistical analyses
Differences between means were evaluated using an unpaired
two-sided Student’s t-test (P < 0.05 considered as significant).
Where appropriate, comparisons of multiple treatment conditions with controls were analyzed by ANOVA with the Dunnett’s
test for post hoc analysis.

Fatty acid uptake and lipolysis assays
WT-passaged HSCs were transduced with or without LV-Plin5YFP, or LV-YFP, or LV-Plin5-YFP plus Ad-L-Fabp. Cells were incubated in media containing 2µCi [3H]oleic acid (ART 0198,
American Radiolabeled Chemicals, St. Louis, MO) and 250 µM
oleic acid albumin (O-3008, Sigma-Aldrich) for 4 h at 37°C,
washed, and extracted with chloroform-methanol as described
(15). Radiolabeled lipids were separated by thin layer chromatography, and the position of 3H-lipids was determined by migration
of unlabeled standards. Assays were performed in triplicate, and
normalized to cellular protein content.
For lipolysis assays, cells (groups as described above) were
collected in PBS and frozen. Cell pellets were homogenized in
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RESULTS
L-Fabp is critical for Plin5-mediated rescue of LD
formation in HSCs
To determine the role of L-Fabp in Plin5-mediated rescue of LD formation, we examined cultured HSCs from
/
mice, transduced with recombinant LVWT and L-Fabp
Plin5-YFP or an empty lentiviral LV-YFP control. As shown
in Fig. 1A, LV-Plin5-YFP (but not the empty vector control)
restored the formation of LDs in activated WT HSCs, demonstrated by staining with Oil Red O. In contrast, LV-Plin5-YFP

Downloaded from www.jlr.org at Washington Univ Medical Library, on March 3, 2018

The RNAi sequences targeting mouse Plin2 mRNA was selected
using online RNAi design program from Thermo Fisher Scientific, Dharmacon RNAi Technologies (Lafayette, CO). Three
shRNA constructs were generated and tested. The best inhibitory
results were from the following Plin2 shRNA sequence: 5′-GGA
CCA AGT CTG TGG TCA A-3′. The anti-sense sequence of the
Plin2 shRNA was used as a negative control. Construction of
shRNA expression cassettes and subsequent cloning in the lentiviral vector pFLRu were conducted as we previously described
(24).

0.25M sucrose, 1 mM EDTA, 1 mM DTT, with protease inhibitors and centrifuged at 1,000 g to remove insoluble material.
Lipase activity was measured using 0.5 µCi [3H]Triolein (ART
0199, American Radiolabeled Chemicals) in the presence of 80
µM glyceryl trioleate (T-7140, Sigma-Aldrich) and 1% FA-free
BSA for 1 h at 37°C. Assays were stopped by the addition of
chloroform-methanol, extracted, and analyzed by thin layer
chromatography as described above, and regions comigrating
with unlabeled oleate were scraped and counted. Data were corrected for nonspecific hydrolysis and normalized to cellular
protein.
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/

failed to restore LD formation in HSCs from L-Fabp mice
(Fig. 1A).
We found that Plin5 was expressed in both freshly isolated WT and L-Fabp/ HSCs (Fig. 1B, C), although the
abundance of Plin5 mRNA was lower in L-Fabp/ (Ct value
≈28.5) compared with WT HSCs (Ct value ≈28.1) (Day 1)
(Fig. 1B). These findings led us to ask whether germline
L-Fabp deletion impaired endogenous Plin5 expression in
freshly isolated HSCs. However, Western blotting analyses
of HSCs revealed comparable abundance of Plin5 at Day 0
in both genotypes (Fig. 1C). We further showed that Plin5
was reduced in HSCs of both genotypes after culture for

7 days (Day 7) (Fig. 1B and C), a time in culture that other
studies have shown quiescent HSCs spontaneously become
fully activated (31). Transduction of LV-Plin5-YFP resulted
in a comparable increase in (exogenous) Plin5 expression
in both passaged-WT and L-Fabp/ HSCs (Fig. 1D). Considered together, these findings reveal expression of Plin5
protein in freshly isolated, quiescent HSCs in both genotypes, albeit at lower abundance than observed in passaged
HSCs transduced with LV-Plin5 (compare Fig. 1C with Fig.
1D), particularly when taking into consideration that 40 µg
total protein was loaded per well in Fig. 1C versus 20 µg
in Fig. 1D. Nevertheless, the data established that Plin5

Downloaded from www.jlr.org at Washington Univ Medical Library, on March 3, 2018

Fig. 1. L-Fabp is critical for Plin5-mediated rescue of LD formation in HSCs. Passaged HSCs from WT mice (wt HSC) and from L-Fabp
germline knockout mice (L-Fabp/HSC) were transduced with the recombinant lentiviral LV-Plin5-YFP or the empty lentiviral LV-YFP, respectively, as a vehicle mock control. Positive transductants were selected with puromycin at 5 g/ml for 48 h. A: Oil Red O staining of cellular LDs. Representative views from three independent experiments are presented. B: Real-time PCR assays of Plin5 in freshly isolated WT
HSCs or L-Fabp/HSCs after culture for 1 day or 7 days (n = 3), *P < 0.05 vs. corresponding HSCs at day 1, and ‡P < 0.05 vs wtHSCs at day 1
(Ct Plin5 in WT HSC ≈28.1; Ct Plin5 in L-Fabp/HSC≈28.5; Ct GAPDH≈18). C: Western blotting analyses of Plin5 in freshly isolated WT
HSCs or L-Fabp/HSCs (D0) or after culture for 7 days (D7) (40 g protein/well was loaded). -actin was used as an invariant control for
equal loading. D: Western blotting analyses of Plin5 in WT HSCs or L-Fabp/HSCs, respectively, transduced with LV-YFP or LV-Plin5-YFP
(20 g protein/well was loaded). E: Real-time PCR analyses of expression of LD protein genes in wt HSCs and in L-Fabp/HSCs (n = 3).
*P < 0.05 vs corresponding control (Ctr). F: Analyses of cellular FFA (n = 3), and cellular TG (n = 3) content following lentiviral transduction;
*P < 0.05 vs. corresponding nontransduced Ctr HSCs. G: Uptake of FA and incorporation into TG in wt HSCs following transduction with or
without LV-YFP, LV-Plin5, or LV-Plin5 plus Ad-L-Fabp (n = 3); *P < 0.01 vs. the CtrHSCs; ‡P < 0.04 vs. HSCs with LV-YFP.
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L-Fabp is required for Plin5-mediated reversal of HSC
activation and transcriptional induction of prolipogenic
signaling pathways
To explore the underlying mechanisms by which Plin5
and L-Fabp function in promoting cellular lipid content,
we asked whether exogenous Plin5 might stimulate prolipogenic and/or attenuate antilipogenic transduction pathways, in a manner dependent on L-Fabp. For this purpose,
we examined LXR and PPAR induction as models of prolipogenic induction (32–34) and also Wnt/-catenin signaling which, via cross-talk with PPAR, interferes with its
functions and is considered antilipogenic (35, 36). We
transduced WT or L-Fabp/ HSCs with LV-Plin5-YFP or
LV-YFP and after selection, transfected those cells with luciferase reporter plasmids LXR-Luc, PPRE-Luc, or TOPFlash (see details in Methods). As shown in Fig. 2A, elevated
luciferase activity was found in LXR-Luc and PPRE-Luctransfected WT but not L-Fabp/ HSCs transduced with
Plin5. Conversely, we observed reduced luciferase activity
in WT but not L-Fabp/ HSCs transfected with TOPFlashLuc and transduced with Plin5.
We further examined mRNA expression of acetyl coA
carboxylase (ACC), FAS, and lectin-like oxidized LDL receptor-1 (LOX-1), which are surrogate downstream target
genes of LXR (37), PPAR (38) and Wnt/-catenin signaling (39), respectively. We found that expression of exogenous Plin5 significantly increased mRNA abundance of
ACC and FAS and reduced LOX-1 mRNA in WT but not
L-Fabp/ HSCs (Fig. 2B). Using the same experimental design, forced expression of Plin5 in WT, but not L-Fabp/
HSCs, significantly inhibited mRNA abundance of -SMA
and I(I) procollagen, two markers of fibrogenic activation
(Fig. 2C). We also found that exogenous Plin5 significantly
reduced mRNA abundance of pro-lipolytic genes patatinlike phospholipase-3, adipose triglyceride lipase (ATGL),
and abhydrolase domain containing 5 (abhd5), in WT but
420
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not L-Fabp/ HSCs (Fig. 2D). These changes were accompanied by induction of SREBP-1 and PPAR mRNAs by 3- to
5-fold (Fig. 2D). As noted above, these effects of exogenous
Plin5 on lipogenic gene expression were not observed in
L-Fabp/ HSCs (Fig. 2D). Taken together, these findings
reinforce the conclusion that L-Fabp deletion significantly
attenuates the ability of Plin5 to inhibit HSC activation and
elevate cellular lipid content, likely through a network of
transcriptional signaling pathways.
Introduction of L-Fabp into L-Fabp/ HSCs rescues
Plin5-mediated reversal of activation and prolipogenic
activity
We introduced Ad L-Fabp (or LacZ control virus) into
/
HSCs as deLV-Plin5-YFP or LV-YFP transduced L-Fabp
tailed in Methods. Western blotting revealed (as expected)
that endogenous L-Fabp in both passaged WT HSCs and
L-Fabp/ HSCs was not detectable, while Ad-L-Fabp transduction led to a comparable increase in L-Fabp expression
in both genotypes (Fig. 3A). Real-time PCR analyses indicated that forced expression of L-Fabp induced expression
of Plin5 in both passaged WT HSCs and L-Fabp/ HSCs
(Fig. 3B) as previously reported (18). As shown in Fig. 3C,
upon rescue of L-Fabp expression in L-Fabp/ HSCs, Plin5
transduction decreased expression of -SMA and I(I)
procollagen mRNAs and also increased mRNA abundance
of SREBP-1 and PPAR (Fig. 3C). Forced L-Fabp expression also restored cellular FFA and TG content in Plin5
transduced L-Fabp/ HSCs (Fig. 3D).
As noted above (Fig. 1A), Plin5 transduction into WT
HSCs led to increased mRNA expression of Plin2. In view
of prior studies demonstrating a role of Plin2 in LD formation in HSCs (40), we sought to clarify the role of Plin2 in
the coordinated interactions of L-Fabp and Plin5 in LD formation. For this purpose, we cultured L-Fabp/ HSCs with
LV-YFP or LV-Plin5, with or without Ad-L-Fabp, in the presence of Plin2 shRNA. This knockdown strategy resulted
in more than 80% Plin2 knockdown efficiency (Fig. 3E).
We confirmed that exogenous Plin5 increased endogenous
Plin2 protein expression in L-Fabp/ HSCs, but Ad-L-Fabp
rescue caused no further upregulation of Plin2 expression
(Fig. 3E). Furthermore, Oil Red O staining revealed that
shRNA inhibition of Plin2 had no effect on LD formation
in L-Fabp/ HSCs transduced with Plin5 and Ad L-Fabp
(Fig. 3E). Finally, to examine the role of L-Fabp and Plin5
in coordinating transcriptional activation of lipogenic
pathways, Ad-L-Fabp infected, Plin5 transduced L-Fabp/
HSCs were transiently transfected with LXR-Luc, PPRELuc, or TOPFlash plasmids as above. Luciferase activity assays
revealed that Ad-L-Fabp rescued Plin5-mediated transcriptional induction in L-Fabp/ HSCs transfected with
LXR-Luc or PPRE-Luc, and, conversely, reduced luciferase
activities in L-Fabp/ HSCs transfected with TOPFlash
(Fig. 3F). These results collectively reinforce the conclusions that expression of exogenous L-Fabp in L-Fabp/
HSCs rescues the ability of Plin5 to reverse HSC activation,
elevate cellular lipid content, and regulate prolipogenic
pathways. Furthermore, these effects appear to be independent of Plin2.
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expression from the lentiviral transduction experiments
reflect a reasonable range of forced overexpression in relation to endogenous levels in freshly isolated HSCs.
Having established these baseline parameters, we next
evaluated the role of Plin5 in regulating cellular lipid content
in HSCs. We found that forced expression of exogenous
Plin5 in both WT and L-Fabp/ HSCs induced expression of
Plin2 (Fig. 1E), but that the expression of other lipid droplet protein genes, including Plin3 and hypoxia-induced
gene 2 (HIG2), were unaffected. We further examined the
coordinated effects of Plin5 and L-Fabp in modulating
cellular lipid content (Fig. 1F). As expected, LV-Plin5-YFP
transduction increased intracellular FFA and TG content
in WT but not L-Fabp/ HSCs (Fig. 1F). In addition, we
found that Plin5 and L-Fabp together promote uptake of
radiolabed FA and TG formation in WT HSCs (Fig. 1G).
These results collectively suggest that L-Fabp plays a permissive role, along with Plin5, in increasing cellular lipid
content and restoring LD formation in WT HSCs. However, for reasons explored below, and despite comparable
expression of exogenous Plin5 following lentiviral transduction, this response fails to occur in L-Fabp/ HSCs.

Supplemental Material can be found at:
http://www.jlr.org/content/suppl/2018/01/09/jlr.M077487.DC1
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Expression of other FABPs in L-Fabp/ HSCs rescues the
ability of Plin5 to restore LD formation
Consistent with the findings above, lentiviral Plin5 restored LD formation in WT HSCs with Ad-LacZ or with
Ad-L-Fabp, suggesting that endogenous expression of
L-Fabp is sufficient for these effects in WT HSCs. However,
LDs were only restored in lentivirally transduced Plin5
L-Fabp/ HSCs transfected with Ad-L-Fabp, but not with
Ad-LacZ (the lower right panel with arrow of the lower
four panels in Fig. 4A). We previously observed that other
FABPs were expressed in quiescent HSCs, albeit at very
low levels relative to L-Fabp (18). To address the question
whether other FABPs could replace L-Fabp in Plin5-mediated rescue of LD formation, WT and L-Fabp/ HSCs
were sequentially transduced with LV-Plin5-YFP or LV-YFP
followed by recombinant adenoviral intestinal Fabp (Ad-IFabp), adipocyte Fabp (Ad-A-Fabp), or Ad-LacZ transduction (Fig. 4B). We found that either Ad-I-Fabp or Ad-A-Fabp

together with Plin5 restored LDs in L-Fabp/ HSCs (panels with arrows in Fig. 4C). In addition, and as found with
the Ad-L-Fabp transduction experiments reported above,
neither Ad-I-Fabp or Ad-A-Fabp transduction alone in
L-Fabp/ HSCs restored LD formation (Fig. 4 C). These
findings again point to a role for endogenous L-Fabp in
LD formation in response to Plin5 transduction in WT
HSCs. Although we did not systematically examine the
entire range of FABPs, our results suggest that the expression of exogenous L-Fabp as well as other FABPs effectively
rescues the ability of Plin5 to restore LD formation in
L-Fabp/ HSCs.
Small molecule inhibitors of L-Fabp impair the ability of
Plin5 to restore LD formation in HSCs
To address how Plin5 induces LD formation through an
L-Fabp-dependent mechanism, we were guided by the finding that exogenous Plin5 significantly increased mRNA
Plin5 regulates lipid droplet formation via L-Fabp
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Fig. 2. L-Fabp is required for Plin5-mediated reversal of HSC activation and transcriptional induction of prolipogenic signaling pathways.
Passaged WT or L-Fabp/HSCs were transduced with LV-Plin5-YFP or LV-YFP. After selection with puromycin, cells were prepared for experiments; *P < 0.05 vs. HSCs transduced with LV-YFP (corresponding solid columns). A: Luciferase activity assays of WT (wt) or L-Fabp/ HSCs
transduced with LV-Plin5-YFP or LV-YFP and followed by transfection with the luciferase reporter plasmids LXR-Luc, PPRE-Luc, or TOPFlash
(n = 6). B: Real-time PCR analyses of downstream target genes of the signaling of SREBP-1 (ACC), PPAR (FAS), and Wnt-1 (LOX-1). C:
Real-time PCR analyses of genes relevant to HSC activation (n = 3). D: Real-time PCR analyses of genes relevant to lipolysis (left panel) and
lipogenesis (right panel) (n = 3).
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abundance of endogenous L-Fabp in WT HSCs (Fig. 5A),
and the transcriptional reporter GFP in our GFP-knockin
L-Fabp/ HSCs (17) (Fig. 5A). Further studies indicated
that the expression of exogenous Plin5 had no apparent
impact on mRNA expression of other FABPs in activated
WT HSCs (Fig. 5B). These findings further reinforce the
concept that endogenous L-Fabp induction may be a key
step in the Plin5-mediated restoration of LDs in WT HSCs.
To examine this possibility directly, we turned to a series of
small molecule inhibitors of L-Fabp function engineered
with varying degrees of specificity and potency (supplemental Fig. S1).
We focused on the most selective L-Fabp inhibitor
(NSOP00313, abbreviated as NSOP313) at increasing doses
in WT HSCs for 24 h before and after transduction with
LV-Plin5-YFP. We found that treatment with NSOP313
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caused a dose-dependent decrease in the formation of LDs
(Fig. 5C), along with decreased cellular FFA and TG
content (Fig. 5E). Moreover, higher doses of NSOP313
triggered upregulation of mRNAs associated with HSC
activation and decreased expression of PPAR mRNA (Fig.
5D).
We also asked whether the effects of Ad-L-Fabp in increasing endogenous Plin5 expression (see Fig. 3B) might
be reversed following L-Fabp inhibitor treatment. Accordingly, NSOP313 at increasing doses was used to treat AdL-Fabp transduced WT HSCs, the data showing a dosedependent reduction in Plin5 mRNA expression (Fig. 5F).
These results together confirm the critical role of L-Fabp
in regulating Plin5 in inhibiting HSC activation, increasing cellular lipid content, and restoring LD formation in
HSCs.
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Fig. 3. Introduction of L-Fabp into L-Fabp/HSCs rescues Plin5-mediated reversal of activation and prolipogenic activity. L-Fabp/HSCs
were transduced with LV-Plin5-YFP or LV-YFP, and in some experiments with Plin2 shRNA, then transduced with recombinant adenoviral
Ad-L-Fabp or the control recombinant adenoviral Ad-LacZ. Twenty-four hours later, cells were prepared for experiments; *P < 0.05 vs. HSCs
transduced with Ad-LacZ (corresponding solid columns). A: Western blotting analyses of L-Fabp in WT (wt) HSC or L-Fabp/HSCs transducted with Ad-L-Fabp or Ad-LacZ, respectively. -actin was an internal control for equal loading. Representative views of three independent
tests are presented. B: Real-time PCR analyses of Plin5 in WT HSC and L-Fabp/HSCs transducted with Ad-L-Fabp or Ad-LacZ (n = 3). C:
Real-time PCR analyses of genes (n = 3). D: Analyses of cellular FFA and TG (n = 3). E: Western blotting analyses of the inhibitory efficiency
of shRNAPlin2 and Oil Red O staining. Representative views from three independent experiments are presented. F: Luciferase activity assays
of the transduced HSCs transfected with the luciferase reporter plasmids LXR-Luc, PPRE-Luc, or TOPFlash(n = 6).
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Fig. 4. Expression of other FABPs in L-Fabp HSCs
rescues the ability of Plin5 to restore LD formation.
Passaged WT (wt) or L-Fabp/HSCs were transduced
with LV-Plin5-YFP or LV-YFP, respectively. After selection with puromycin, cells were transduced with Ad-LFabp or Ad-LacZ (A and B) or were transduced with a
recombinant adenovirus expressing I-Fabp (Ad-I-Fabp)
or A-Fabp (Ad-A-Fabp) (C). Representative views from
three independent experiments are presented. A: Oil
Red O staining of LDs in HSCs transduced with AdL-Fabp or Ad-LacZ. B: Western blotting analyses of
I-Fabp or A-Fabp. C: Oil Red O staining of LDs in HSCs
transduced with Ad-I-Fabp, Ad-A-Fabp, or Ad-LacZ.

DISCUSSION
We recently reported that the activation of HSCs was
temporally coincident with the loss of LDs, the depletion of

Plin5 (8), and the suppression of L-Fabp expression (18)
both in vitro and in vivo. The current findings extend those
observations by demonstrating that exogenous Plin5 induces endogenous L-Fabp expression in WT HSCs, suggesting a requirement for L-Fabp in the rescue of quiescence
mediated by Plin5. We further show that either lifelong
absence of L-Fabp (in L-Fabp/ HSCs) or pharmacologic
inhibition of endogenous L-Fabp in WT HSCs abrogated the ability of Plin5 to reverse HSC activation and also
eliminated LD formation and lipid accumulation. Conversely, adenoviral-mediated expression of exogenous
L-Fabp in L-Fabp/ HSCs rescued the ability of Plin5 to
restore quiescence. Accordingly, a central conclusion of
this work is that L-Fabp is required for Plin5-mediated rescue of cellular quiescence in HSCs, through pathways that
intersect with the induction of lipogenic gene programs.
That being said, we recognize that the range of functions of
Plin5 implied from studies in animal models is still controversial (9, 41).
Accumulating evidence has shown the importance of
cellular lipids in maintaining HSCs in a state of quiescence,
although the precise roles of key LD proteins remain elusive. At the molecular level, independent work strongly
supports the idea that Plin5 functions as a scaffold for three
major key lipolytic players, abhd5, ATGL, and hormonesensitive lipase, in hydrolysis of TG in LDs (42–45). Plin5 is
highly expressed in oxidative tissues such as skeletal muscle, liver, and heart and is central to lipid homeostasis in
these tissues. Studies in cell systems have ascribed several
metabolic roles to Plin5 and demonstrated interactions
with other proteins that are requisite for these functions
(41). Our results support an important role for Plin5 in
elevating cellular lipid content in HSCs (8); namely, induction of lipogenic pathways through transcriptional activation of SREBP and PPAR dependent pathways. We
recognize that further studies will be required to explore
the precise mechanisms of increased de novo lipogenesis
observed.
Studies suggest that lecithin-retinol acyltransferase
(LRAT) acts as the sole retinol acyltransferase in the liver
and is responsible for the formation of retinyl esters in
HSCs (46). LRAT is highly expressed in quiescent HSCs
and downregulated during HSC activation (47). Lrat /
Plin5 regulates lipid droplet formation via L-Fabp
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AMPK activation is required for L-Fabp-mediated
Plin5-dependent restoration of lipogenesis and
/
HSCs
quiescence in L-Fabp
We previously reported that exogenous Plin5 stimulated
AMPK activation in WT HSCs, which in turn induced the
expression of endogenous Plin5, a pathway required for
restoring LD formation and inhibiting HSC activation (8).
To address the role of AMPK activation in the coordination
of L-Fabp with Plin5, we first explored the requirement of
L-Fabp in the activation of AMPK by Plin5 in L-Fabp/
HSCs. As shown in Fig. 6A, forced expression of exogenous
Plin5 increased the abundance of phosphorylated AMPK
in both WT and L-Fabp/ HSCs. By contrast, forced
expression of L-Fabp alone could not activate AMPK
in L-Fabp/ HSCs (Fig. 6A). These findings suggest that
L-Fabp is not required for Plin5 to activate AMPK in HSCs.
They also suggest that the introduction of Ad-L-Fabp alone
into L-Fabp/ HSCs is not sufficient for AMPK activation.
We further studied L-Fabp/ HSCs transduced with LVPlin5-YFP or LV-YFP and subsequent Ad-L-Fabp rescue, followed by treatment with the selective AMPK inhibitor
Compound C at 20 M for 24 h. AMPK inhibition significantly attenuated the effects of Plin5 and L-Fabp on regulating expression of genes relevant to HSC activation,
lipogenesis, and lipolysis in L-Fabp/ HSCs (Fig. 6B) and
also attenuated LD formation (Fig. 6C). Additionally,
AMPK inhibition dose-dependently reversed Plin5-dependent
increases in endogenous L-Fabp mRNA in WT HSCs (Fig.
6D). These findings suggest that Plin5-induced expression
of endogenous L-Fabp in HSCs is likely AMPK-dependent.
AMPK inhibition also reversed the transcriptional programs of lipogenic induction of LXR and PPAR and of
Wnt suppression as indicated by the luciferase assays using
reporter constructs outlined above (Fig. 6E). Taken together, these results strongly suggest that AMPK activation
is required for the coordination of L-Fabp with Plin5 in
mediating rescue of quiescence in L-Fabp/ HSCs.

Supplemental Material can be found at:
http://www.jlr.org/content/suppl/2018/01/09/jlr.M077487.DC1
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mice showed a striking total absence of large lipid-containing
droplets that normally store hepatic retinoid within HSCs
(48). However, the absence of retinyl ester-containing
LDs does not promote either spontaneous HSC activation, or worsen bile duct ligation-induced or carbon tetrachloride-induced liver fibrosis (47). Our earlier studies
showed that exogenous Plin5 had no impact on the expression of endogenous LRAT in WT HSCs (8). We considered the possibility that Plin5 and L-Fabp transduction
might modify retinol content of HSCs but our findings
demonstrated only very low levels of retinol with no differences by genotype and retinyl esters were undetectable (supplemental Table S1). Because these studies were
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undertaken in passaged HSCs, those findings would be
predicted.
Our findings also highlight a potential functional redundancy in the FABP requirement for Plin5-dependent rescue of quiescence and LD formation. We have previously
shown that among all FABPs, L-Fabp is by far the most
abundantly expressed member in quiescent HSCs (18).
Other FABP members in quiescent HSCs are either expressed at a very low level or their expression is unchanged
during HSC activation (18). We observed that exogenous
Plin5 in WT HSCs induced endogenous L-Fabp expression,
but not other FABP members (Fig. 5B), suggesting specificity in Plin5-dependent effects via L-Fabp in promoting LD
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Fig. 5. Small molecule inhibitors of L-Fabp impede the ability of Plin5 to restore LD formation in HSCs. A: Passaged WT (wt) HSCs or
L-Fabp/HSCs were transduced with LV-Plin5-YFP or LV-YFP. Total RNA was prepared for real-time PCR analyses; *P < 0.05 vs. HSCs transduced with LV-YFP (corresponding solid columns) (n = 3). B: Real-time PCR analyses of WT HSCs transduced with LV-Plin5-YFP or LV-YFP.
All data were normalized to the expression of L-Fabp in HSCs with LV-YFP; *P < 0.05 vs. HSCs transduced with LV-YFP (corresponding solid
columns) (n = 3). C–E: WT HSCs were transduced with LV-Plin5-YFP followed by treatment with the selective L-Fabp inhibitor NSOP00313
(referred to as NSOP313 in text) at the indicated doses for 24 h. C: Oil Red O staining of cellular LDs (Representative views from three independent experiments are presented) and the numbers of LDs per cell (mean from 10 cells). D: Real-time PCR analyses; *P < 0.05 vs. HSCs
without NSOP313 treatment (n = 3). E: Analyses of cellular FFA and TG content. *P < 0.05 vs. HSCs without NSOP313 treatment (n = 3).
F: Real-time PCR analyses of endogenous Plin5 mRNA in Ad-L-Fabp transduced WT HSCs with treatment of NSOP313 at the indicated doses.
*P < 0.05 vs. HSCs without NSOP313 treatment.
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formation and restoration of quiescence. On the other
hand, our findings also suggest that L-Fabp is not functionally unique and its role could be replicated by other FABPs,
including I-Fabp or A-Fabp. Although we did not undertake a comprehensive evaluation of the entire FABP family,
it is tempting to speculate that under circumstances where
other FABPs might be induced (not examined here), there
may yet be L-Fabp-independent pathways of restoring quiescence. Along these lines, whereas we found that the
most specific and potent small molecule L-Fabp inhibitor
(NSOP313) effectively replicated the phenotypes observed
with L-Fabp deletion (Fig. 5), we also found that other
L-Fabp inhibitors (supplemental Fig. S1) showed similar effects but were either less selective or more toxic.
Our earlier work suggested that germline L-Fabp deletion functions to attenuate high-fat, fibrogenic, dietinduced hepatic steatosis and fibrosis, raising the possibility
that inhibition of L-Fabp might be a feasible strategy to
mitigate the effects of hepatic steatosis and necroinflammatory disease progression. However, it bears emphasis

that L-Fabp is abundantly expressed in hepatocytes as well
as in HSCs and it is possible that its roles and functions are
exerted in a distinct cell- and metabolic-state-specific context. The current findings support the concept of this
cell-type-specific function by demonstrating that genetic
deletion or pharmacologic inhibition of L-Fabp essentially
eliminates the ability of Plin5 to restore LD formation in
either WT or L-Fabp/ HSCs. The findings from these in
vitro studies additionally suggest that pharmacologic inhibition of L-Fabp, by mitigating LD formation and induction of a lipogenic program, might simultaneously induce
HSC activation.
An overarching question in our approach relates to
whether the expression levels of exogenous Plin5 are reflective of those encountered physiologically. We demonstrated that Plin5 protein is indeed detectable in freshly
isolated HSCs, albeit at levels somewhat lower than those
seen with forced lentiviral expression in passaged HSCs
(Fig. 1C, D). In addition, we previously reported that transduction of WT HSCs with LV-Plin5-YFP or the empty
Plin5 regulates lipid droplet formation via L-Fabp
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Fig. 6. AMPK activation is required for L-Fabp-dependent Plin5-mediated restoration of lipogenesis and quiescence in L-Fabp/HSCs. A:
Western blotting analyses of phosphorylated AMPK (p-AMPK) in WT HSCs or in L-Fabp/HSCs transduced with recombinant virus as indicated. Total AMPK abundance was used as an internal control for equal loading. Representative views from 3 independent experiments are
presented; (B, C, and E). L-Fabp/HSCs were sequentially transduced with LV-Plin5-YFP or LV-YFP, and then with Ad-L-Fabp, followed by
treatment with the AMPK inhibitor Compound C (CompdC), at the indicated concentrations. B: Real-time PCR analyses (n = 3); *P < 0.05
vs. HSCs transduced with LV-YFP (corresponding solid columns). C: Oil Red O staining of cellular LDs. Representative views from three independent experiments are presented. D: Real-time PCR analyses of endogenous L-Fabp in WT HSC transduced with LV-Plin5 (n = 3); *P <
0.05 vs. HSCs with no CompdC. E: Luciferase activity assays of the transduced HSCs transfected with the luciferase reporter plasmids LXRLuc, PPRE-Luc, or TOPFlash (n = 6).
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Fig. 7. Summary overview of the proposed pathways explored in
this report. Stellate cell (HSC) activation is temporally accompanied by loss of lipid droplets (LDs) along with decreased expression
of both Plin5 and L-Fabp. Lentiviral (LV) transduction of Plin5 into
WT HSCs restores exogenous (exo) Plin5, leading to AMPK activation and increased endogenous L-Fabp expression which in combination further increases endogenous (endo) Plin5 expression. The
coordination of Plin5 and L-Fabp promotes lipid (fatty acid) uptake
and increases lipogenesis, leading to the elevation of cellular lipid
content. Upregulation of endogenous L-Fabp is a requisite step in
this pathway, the net effects leading to accumulation of LDs and a
return to quiescence with HSC deactivation.

L-Fabp → AMPK activation). This suggestion is supported
by experiments showing that, although forced expression
of Plin5 induced expression of endogenous L-Fabp in WT
HSCs (Fig. 5A), inhibition of Plin5 signaling by AMPK inhibition dose-dependently reduced L-Fabp expression. These
findings beg the question of whether AMPK activation
modulates L-Fabp expression, which is a subject of future
investigation.
Forced expression of L-Fabp elevated the mRNA level of
endogenous Plin5 by 2- to 3-fold in both WT HSCs and in
L-Fabp/ HSCs (Fig. 3B), consistent with our prior observations (18). However, forced expression of exogenous
L-Fabp itself did not inhibit expression of HSC activationrelevant genes (Fig. 3C), augment cellular lipid content
(Fig. 3D), nor rescue LD formation in L-Fabp/ HSCs (Fig.
4A). These observations imply that despite the ability of
forced L-Fabp expression to increase endogenous Plin5
mRNA by 2- to 3-fold, the levels of Plin5 protein remain
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control virus LV-YFP shows significant differences in inhibiting HSC activation (8). Introduction of LV-Plin5-YFP, but
not LV-YFP, significantly reduces cell growth and expression of activation-relevant genes and restores LD formation
in HSCs. Additionally, we showed that the major functional
domain of Plin5 for the LD formation in HSCs resided in
a domain spanning amino acids 1–188 (aa1–188) of Plin5
(8) and that overexpression of a subdomain of Plin5
(aa189–463) had no function in LD formation. These prior
results, coupled with the new findings shown in Fig. 1C and
D, greatly diminish the possibility of a neomorphic phenotype of Plin5 transduction or of an artifact derived from
nonspecific recombinant lentiviral transduction.
It was reported that introduction of Plin2 promotes
downregulation of HSC activation and is functionally
linked to the expression of fibrogenic genes (40). We observed that forced expression of Plin5 was coupled with the
expression of endogenous Plin2 in HSCs (Fig. 1E). Inhibition of the Plin2 expression by Plin2 shRNA showed no
impact on the Plin5 function in restoring LD in HSCs (Fig.
3E). Our results and others suggest that Plin5, Plin2, or
even other lipid droplet proteins, could independently
function in HSCs.
Plin5 was reported to be phosphorylated by protein kinase A (PKA) (49–51), and the serine at 155 in Plin5 has
been proposed as the PKA phosphorylation site (50). Phosphorylation of Plin5 by PKA stimulated the interaction of
Plin5 and ATGL (51), which might play a critical role in
Plin5-regulated lipolysis (50). Plin5 has been proposed to
be an important molecular link that couples the coordinated catecholamine activation of the PKA pathway and of
lipid droplet lipolysis with transcriptional regulation to
promote efficient fatty acid catabolism (49). The possibility
that Plin5 modulates lipid hydrolysis in HSCs and the role,
if any, for L-Fabp will require further study.
AMPK is a well-conserved serine/threonine-protein kinase, which acts as a cellular energy and nutrient sensor
and plays a crucial role in regulation of metabolic pathways
and cellular energy homeostasis (52). Phosphorylation of
AMPK at Thr-172 stimulates its kinase activity (53). AMPK
acts as an anti-lipolytic factor by phosphorylating and inactivating hormone-sensitive lipase (54) and blocking its
translocation to LDs (55). We previously showed that the
activation of AMPK increased cellular TG in HSCs and inhibited activation (29). We also showed that PKA and
AMPK played opposite roles in regulating HSC activation
(56). In the current study, we observed that activation of
AMPK played a key role in the coordination of L-Fabp with
Plin5 in inhibiting HSC activation and restoring LD formation. Our findings lead us to hypothesize that a positivefeedback loop exists between Plin5 and AMPK activation in
HSCs in which expression of Plin5 results in activation of
AMPK and induction of pro-lipogenic genes (Fig. 7).
Our results also suggest that forced expression of Plin5
stimulated AMPK activation in WT and L-Fabp/ HSCs.
However, overexpression of exogenous L-Fabp alone could
not activate AMPK. These results suggest that AMPK might
be a downstream target of Plin5, and upstream of L-Fabp
(i.e., Plin5 → AMPK activation → L-Fabp; not Plin5 →
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below the threshold necessary for complete rescue of quiescence as previously observed in WT HSCs (18). In addition, as noted above, the introduction of Ad-L-Fabp alone
into L-Fabp/ HSCs failed to activate AMPK. Based on the
collective observations presented above, a simplified model
is proposed to address the role of AMPK and L-Fabp in
mediating/coordinating the effects of Plin5 in restoring
HSC quiescence (Fig. 7). It bears emphasis that this model
does not exclude other pathways by which L-Fabp functions in coordinating with Plin5 the inhibition of HSC activation. In summary, our results demonstrate that L-Fabp
plays a critical role in coordinating with Plin5 in modulating expression of lipogenic genes, restoring LD formation,
elevating lipid content, and inhibiting HSC activation.
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